Skip to main content

Mercaptopurine Disease Interactions

There are 5 disease interactions with mercaptopurine.

Major

Antineoplastics (applies to mercaptopurine) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

Switch to professional interaction data

Major

Mercaptopurine (applies to mercaptopurine) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Mercaptopurine is hepatotoxic. Hepatic injury can occur at any dosage, however, increased frequency of injury occurs when doses exceed 2.5 mg/kg/day. Deaths due to hepatic necrosis have been reported. Patients should be instructed to immediately report any signs of hepatotoxicity such as jaundice, hepatic dysfunction such as, jaundice, dark urine, right upper quadrant pain, or anorexia. Therapy with mercaptopurine should be administered cautiously in patients with or predisposed to compromised hepatic function. Clinical monitoring of hepatic function and determination of the etiology of hepatic dysfunction is recommended.

Switch to professional interaction data

Major

Mercaptopurine (applies to mercaptopurine) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bleeding, Bone Marrow Depression/Low Blood Counts, Fever

Mercaptopurine induces dose-related myelosuppression which can be delayed. Leukopenia, thrombocytopenia, and anemia have been reported during mercaptopurine therapy. Therapy should be administered cautiously in patients with myelosuppression and therapy should be withheld at the first indication of an abnormally large reduction of any bone marrow element. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close monitoring of hematopoietic function is recommended.

Switch to professional interaction data

Major

Thioguanine (applies to mercaptopurine) TMPT enzyme deficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Enzymopathy (Unspecified)

Thioguanine is closely related structurally and functionally to mercaptopurine. A rare deficiency in the enzyme thiopurine methyltransferase (TMPT) results in an increased sensitivity to the myelosuppressive effects of both drugs causing rapid bone marrow suppression following initial mercaptopurine or thioguanine administration. Therapy with thioguanine or mercaptopurine should be administered cautiously and at a reduced dose in patients with TMPT deficiency.

Switch to professional interaction data

Moderate

Mercaptopurine (applies to mercaptopurine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Mercaptopurine is excreted in the urine as unchanged drug and metabolites. Renal elimination may be reduced in patients with impaired renal function. Therapy with mercaptopurine should be initiated at a reduced dosage in patients with compromised renal function. Clinical monitoring of renal function is recommended.

Switch to professional interaction data

Mercaptopurine drug interactions

There are 275 drug interactions with mercaptopurine.

Mercaptopurine alcohol/food interactions

There is 1 alcohol/food interaction with mercaptopurine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.